Genetic Variability of GCKR Alters Lipid Profiles in Children with Monogenic and Autoimmune Diabetes

Abstract

Purpose: Mutations in the glucokinase (GCK) gene are associated with altered blood glucose and lipid concentrations. Our aim was to assess the effects on HbA1c and serum lipid levels of single nucleotide polymorphisms (SNPs) in 2 genes encoding proteins that interact with glucokinase: glucose-6-phospatase catalytic subunit 2 (G6PC2) and glucokinase regulatory protein (GCKR).

Methods: The study group included 129 children with GCK-MODY from the Polish Registry of Monogenic Diabetes and 395 with type 1 diabetes (T1DM), in whom we genotyped 2 SNPs in G6PC2 (rs560887) and GCKR (rs1260326). Lipid concentrations were assessed in fasting serum samples.

Results: Total and HDL cholesterol concentrations were significantly lower in the GCK-MODY group than in patients with T1DM (167.5±32.5 mg/dl vs. 174.4±31.1 mg/dl, p=0.0435 and 48.42±14.3 mg/dl vs. 58.7±12.7 mg/dl, p<0.0001, respectively). No differences in genotype distributions were found except for underrepresentation of GCKR TT homozygotes among GCK-MODY patients (10.9% in GCK-MODY vs. 17.7% in T1DM, p=0.0651). GCKR genotypes showed significant associations with lipid profiles and HbA1c levels, whereas no such associations were noted for G6PC2. After adjustment for confounders, TT homozygotes were shown to have higher total cholesterol and marginally higher LDL cholesterol and triglyceride levels (p=0.0245, p=0.0657 and p=0.0550, respectively). The difference between TT homozygotes and other genotypes was similar in magnitude within the GCK-MODY and T1DM groups. No significant interactions between the type of diabetes and the GCKR or G6PC2 genotype were detected.

Conclusions: Individuals who are homozygous TT at rs1260326 of the GCKR gene have higher triglyceride, total and LDL cholesterol levels regardless of the presence of GCK mutations.

Key words

diabetes - fatty acid synthesis - MODY

^* equally contributed to this work.

• References

• 1 Hindorff LA, MacArthur J, Morales J et al. A Catalog of Published Genome-Wide Association Studies. Accessed 3^rd October 2013
• 2 Pound LD, Oeser JK, O’Brien TP et al. G6PC2: a negative regulator of basal glucose-stimulated insulin secretion. Diabetes 2013; 62: 1547-1556
• 3 Bouatia-Naji N, Rocheleau G, Van Lommel L et al. A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. Science 2008; 320: 1085-1088
• 4 Demirci FY, Dressen AS, Hamman RF et al. Association of a Common G6PC2 Variant with Fasting Plasma Glucose Levels in Non-Diabetic Individuals. Annals of Nutrition and Metabolism 2010; 56: 59-64
• 5 Sanda S, Wei S, Rue T et al. A SNP in G6PC2 predicts insulin secretion in type 1 diabetes. Acta Diabetol 2013; 50: 459-462
• 6 Arden SD, Zahn T, Steegers S et al. Molecular cloning of a pancreatic islet-specific glucose-6-phosphatase catalytic subunit-related protein. Diabetes 1999; 48: 531-542
• 7 Newgard CB, Lu DH, Jensen MV et al. Stimulus/secretion coupling factors in glucose-stimulated insulin secretion – Insights gained from a Multidisciplinary approach. Diabetes 2002; 51: S389-S393
• 8 Vanschaftingen E. Short-Term Regulation of Glucokinase. Diabetologia 1994; 37: S43-S47
• 9 Beck T, Miller BG. Structural basis for regulation of human glucokinase by glucokinase regulatory protein. Biochemistry 2013; 52: 6232-6239
• 10 Santoro N, Zhang CK, Zhao HY et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 2012; 55: 781-789
• 11 Mohas M, Kisfali P, Jaromi L et al. GCKR gene functional variants in type 2 diabetes and metabolic syndrome: do the rare variants associate with increased carotid intima-media thickness?. Cardiovascular Diabetology 2010; 9
• 12 Vaxillaire M, Cavalcanti-Proenca C, Dechaume A et al. The common P446L polymorphism in GCAR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population. Diabetes 2008; 57: 2253-2257
• 13 Rees MG, Ng D, Ruppert S et al. Correlation of rare coding variants in the gene encoding human glucokinase regulatory protein with phenotypic, cellular, and kinetic outcomes. Journal of Clinical Investigation 2012; 122: 205-217
• 14 Johansen CT, Wang JA, Lanktree MB et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nature Genetics 2010; 42 684-687
• 15 Fendler W, Borowiec M, Antosik K et al. HDL cholesterol as a diagnostic tool for clinical differentiation of GCK-MODY from HNF1A-MODY and type 1 diabetes in children and young adults. Clin Endocrinol (Oxf) 2011; 75: 321-327
• 16 Tinto N, Zagari A, Capuano M et al. Glucokinase gene mutations: structural and genotype-phenotype analyses in MODY children from South Italy. PLoS One 2008; 3: e1870
• 17 Meininger GE, Scott R, Alba M et al. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 2011; 34: 2560-2566
• 18 Borowiec M, Fendler W, Dusatkova P et al. HbA1c-based diabetes diagnosis among patients with glucokinase mutation (GCK-MODY) is affected by a genetic variant of glucose-6-phosphatase (G6PC2). Diabetic Medicine 2012; 29: 1465-1469
• 19 Choi JM, Seo MH, Kyeong HH et al. Molecular basis for the role of glucokinase regulatory protein as the allosteric switch for glucokinase. Proc Natl Acad Sci USA 2013; 110: 10171-10176
• 20 Borowiec M, Fendler W, Antosik K et al. Doubling the referral rate of monogenic diabetes through a nationwide information campaign – update on glucokinase gene mutations in a Polish cohort. Clinical Genetics 2012; 82: 587-590
• 21 Abecasis GR, Altshuler D, Auton A et al. A map of human genome variation from population-scale sequencing. Nature 2010; 467: 1061-1073
• 22 Altshuler DM, Gibbs RA, Peltonen L et al. Integrating common and rare genetic variation in diverse human populations. Nature 2010; 467: 52-58
• 23 Fendler W, Baranowska AI, Mianowska B et al. Three-year comparison of subcutaneous insulin pump treatment with multi-daily injections on HbA1c, its variability and hospital burden of children with type 1 diabetes. Acta Diabetologica 2012; 49: 363-370
• 24 Fendler W, Borowiec M, Baranowska-Jazwiecka A et al. Prevalence of monogenic diabetes amongst Polish children after a nationwide genetic screening campaign. Diabetologia 2012; 55: 2631-2635
• 25 Saxena R, Voight BF, Lyssenko V et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316: 1331-1336
• 26 Alfred T, Ben-Shlomo Y, Cooper R et al. Associations between a Polymorphism in the Pleiotropic GCKR and Age-Related Phenotypes: The HALCyon Programme. PloS one 2013; 8
• 27 Mesotten D, Swinnen JV, Vanderhoydonc F et al. Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. J Clin Endocrinol Metab 2004; 89: 219-226
• 28 Rivellese AA, Patti L, Romano G et al. Effect of insulin and sulfonylurea therapy, at the same level of blood glucose control, on low density lipoprotein subfractions in type 2 diabetic patients. J Clin Endocrinol Metab 2000; 85: 4188-4192
• 29 Capuano M, Garcia-Herrero CM, Tinto N et al. Glucokinase (GCK) Mutations and Their Characterization in MODY2 Children of Southern Italy. Plos One 2012; 7
• 30 Tanaka D, Nagashima K, Sasaki M et al. GCKR mutations in Japanese families with clustered type 2 diabetes. Mol Genet Metab 2011; 102: 453-460
• 31 Schwab KO, Doerfer J, Scheidt-Nave C et al. Algorithm-Based Cholesterol Monitoring in Children with Type 1 Diabetes. J Pediatr 2014;